NYSE:MRNA - Moderna Inc (NASDAQ) Stock Price, News, & Analysis

+0.37 (+2.40 %)
(As of 06/18/2019 01:17 AM ET)
Today's Range
Now: $15.77
50-Day Range
MA: $21.66
52-Week Range
Now: $15.77
Volume1.22 million shs
Average Volume1.10 million shs
Market Capitalization$5.19 billion
P/E RatioN/A
Dividend YieldN/A
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$5.19 billion
Next Earnings Date8/8/2019 (Estimated)

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

Moderna Inc (NASDAQ) (NYSE:MRNA) Frequently Asked Questions

What is Moderna Inc (NASDAQ)'s stock symbol?

Moderna Inc (NASDAQ) trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRNA."

How were Moderna Inc (NASDAQ)'s earnings last quarter?

Moderna Inc (NASDAQ) (NYSE:MRNA) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.05. The business had revenue of $16.03 million for the quarter, compared to analysts' expectations of $33.59 million. View Moderna Inc (NASDAQ)'s Earnings History.

When is Moderna Inc (NASDAQ)'s next earnings date?

Moderna Inc (NASDAQ) is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Moderna Inc (NASDAQ).

What is the consensus analysts' recommendation for Moderna Inc (NASDAQ)?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna Inc (NASDAQ) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moderna Inc (NASDAQ).

Has Moderna Inc (NASDAQ) been receiving favorable news coverage?

Press coverage about MRNA stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Moderna Inc (NASDAQ) earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Moderna Inc (NASDAQ).

Who are some of Moderna Inc (NASDAQ)'s key competitors?

What other stocks do shareholders of Moderna Inc (NASDAQ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna Inc (NASDAQ) investors own include Zynerba Pharmaceuticals (ZYNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Ra Pharmaceuticals (RARX), Amarin (AMRN), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Motus GI (MOTS) and Synthorx (THOR).

Who are Moderna Inc (NASDAQ)'s key executives?

Moderna Inc (NASDAQ)'s management team includes the folowing people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Chairman & Member of Technology Advisory Board (Age 56)
  • Mr. Stéphane Bancel, CEO & Director (Age 46)
  • Dr. Stephen Hoge, Pres (Age 43)
  • Dr. Lorence H. Kim, Chief Financial Officer (Age 45)
  • Jennifer Lee, Chief Accounting Officer

When did Moderna Inc (NASDAQ) IPO?

(MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

How do I buy shares of Moderna Inc (NASDAQ)?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Moderna Inc (NASDAQ)'s stock price today?

One share of MRNA stock can currently be purchased for approximately $15.77.

How big of a company is Moderna Inc (NASDAQ)?

Moderna Inc (NASDAQ) has a market capitalization of $5.19 billion. Moderna Inc (NASDAQ) employs 760 workers across the globe.View Additional Information About Moderna Inc (NASDAQ).

What is Moderna Inc (NASDAQ)'s official website?

The official website for Moderna Inc (NASDAQ) is http://www.modernatx.com/.

How can I contact Moderna Inc (NASDAQ)?

The company can be reached via phone at 617-714-6500.

MarketBeat Community Rating for Moderna Inc (NASDAQ) (NYSE MRNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  12
MarketBeat's community ratings are surveys of what our community members think about Moderna Inc (NASDAQ) and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Featured Article: Options Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel